Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsUnitedHealthcare FcRn Blockers Prior Auth | OpenPa…
    Ask Trek AI about this page
    ModifiedUnitedHealthcarePolicy 2026D0111P

    FcRn Blockers

    Customize your policy alerts

    Sign up for UnitedHealthcare Policy 2026D0111P alerts

    Get alerted when Policy 2026D0111P changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Commercial medical-benefit coverage and prior authorization for healthcare-professional-administered FcRn blockers used to treat generalized myasthenia gravis and CIDP, including Imaavy, Rystiggo, Vyvgart, and Vyvgart Hytrulo.

    Policy Summary
    PayerUnitedHealthcare
    PolicyFcRn Blockers
    Policy CodePolicy 2026D0111P
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit antibody-status and treatment-failure documentation supporting the applicable generalized myasthenia gravis criteria.
    SourceLink
    POLICY UPDATE CHANGES

    Generalized myasthenia gravis serologic eligibility was revised.

    A treatment-failure requirement was added for anti-MuSK antibody-positive patients.

    ICD-10 diagnosis code G70.0 was added to the applicable codes.

    Policy information and references were updated.

    4Products addressed
    ≥5Baseline MG-ADL
    ≥2 pointsContinuation response

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    12 months
    Authorization period
    63 daysRystiggo cycle interval
    G70.0Added diagnosis code

    Coverage Criteria

    Imaavy — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming that the patient has not failed a previous course of Imaavy therapy.
    • Diagnosis of generalized myasthenia gravis (gMG).
    • ONE of the following

      • Positive serologic test for anti-acetylcholine receptor (AChR) antibodies.
      • Positive serologic test for anti-muscle-specific tyrosine kinase (MuSK) antibodies.
    • Myasthenia Gravis Foundation of America (MGFA) Clinical Classification of class II, III, or IV at initiation of therapy.
    • Myasthenia Gravis Activities of Daily Living scale (MG-ADL) total score ≥ 5 at initiation of therapy.
    • ONE of the following treatment-failure pathways

      • If anti-AChR antibody positive

        • History of failure of at least two immunosuppressive agents over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.).
        • History of failure of at least one immunosuppressive therapy and required four or more courses of plasmapheresis/plasma exchanges and/or immune globulin over the course of at least 12 months without symptom control.
      • If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.).
    • Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody [e.g., Uplizna (inebilizumab)], complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)], FcRn blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)], or immune globulin (e.g., Hizentra, Privigen, Gammagard).
    • Imaavy is dosed according to the U.S. Food and Drug Administration (FDA)-labeled dosing for gMG.
    • Prescribed by, or in consultation with, a neurologist.
    • Initial authorization will be for no more than 12 months.

    Imaavy — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously been treated with Imaavy.
    • Submission of medical records (e.g., chart notes, laboratory tests) demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline.
    • Reduction in signs and symptoms of myasthenia gravis.
    • Maintenance, reduction, or discontinuation of dose(s) of baseline immunosuppressive therapy (IST) prior to starting Imaavy.

      Add-on therapy, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Imaavy therapy will be considered treatment failure.

    • Patient is not receiving Imaavy in combination with a CD19-directed cytolytic antibody [e.g., Uplizna (inebilizumab)], complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)], FcRn blocker [e.g., Rystiggo (rozanolixizumab-noli), Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)], or immune globulin (e.g., Hizentra, Privigen, Gammagard).

    Rystiggo — Initial Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming that the patient has not failed a previous course of Rystiggo therapy.
    • Diagnosis of generalized myasthenia gravis (gMG).
    • ONE of the following

      • Positive serologic test for anti-AChR antibodies.
      • Positive serologic test for anti-MuSK antibodies.
    • MGFA Clinical Classification of class II, III, or IV at initiation of therapy.

    Rystiggo — Continuation Therapy

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously been treated with Rystiggo.
    • Submission of medical records (e.g., chart notes, laboratory tests) demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline.
    • Reduction in signs and symptoms of myasthenia gravis.
    • Maintenance, reduction, or discontinuation of dose(s) of baseline IST prior to starting Rystiggo.

      Add-on therapy, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Rystiggo therapy will be considered treatment failure.

    • Patient is not receiving Rystiggo in combination with a CD19-directed cytolytic antibody [e.g., Uplizna (inebilizumab)], complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)], FcRn blocker [e.g., Imaavy (nipocalimab-aahu), Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)], or immune globulin (e.g., Hizentra, Privigen, Gammagard).

    Vyvgart/Vyvgart Hytrulo — Initial Therapy for gMG

    Covered when ALL of the following are met:

    ALL of the following

    • Submission of medical records (e.g., chart notes, laboratory values, etc.) confirming that the patient has not failed a previous course of Vyvgart therapy.
    • Submission of medical records confirming that the patient has not failed a previous course of Vyvgart Hytrulo therapy.
    • Diagnosis of generalized myasthenia gravis (gMG).
    • ONE of the following antibody-status pathways

      • Positive serologic test for anti-AChR antibodies.
      • Positive serologic test for anti-MuSK antibodies.

    Vyvgart/Vyvgart Hytrulo — Continuation Therapy for gMG

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously been treated with Vyvgart or Vyvgart Hytrulo.
    • Submission of medical records (e.g., chart notes, laboratory tests) demonstrating improvement and/or maintenance of at least a 2-point improvement (reduction in score) in the MG-ADL score from pre-treatment baseline.
    • Reduction in signs and symptoms of myasthenia gravis.
    • Maintenance, reduction, or discontinuation of dose(s) of baseline IST prior to starting Vyvgart or Vyvgart Hytrulo.

      Add-on therapy, dose escalation of IST, or additional rescue therapy from baseline to treat myasthenia gravis or exacerbation of symptoms while on Vyvgart or Vyvgart Hytrulo therapy will be considered treatment failure.

    gMG Continuation Therapy — Applicable Requirements

    For continuation of gMG therapy with Vyvgart or Vyvgart Hytrulo, all applicable continuation requirements must be satisfied, including documented clinical response, appropriate dosing, prescriber qualifications, and the prohibition on combination use with specified therapies.

    ALL of the following

    • Patient has previously been treated with Vyvgart or Vyvgart Hytrulo.
    • Documentation demonstrates improvement and/or maintenance of at least a 2-point improvement (reduction in score) in MG-ADL from pre-treatment baseline and reduction in signs and symptoms of myasthenia gravis.
    • Baseline IST is maintained, reduced, or discontinued; add-on IST, IST dose escalation, or additional rescue therapy to treat myasthenia gravis or exacerbation while on therapy is considered treatment failure.
    • Vyvgart or Vyvgart Hytrulo is not used in combination with a CD19-directed cytolytic antibody, complement inhibitor, FcRn blocker, or immune globulin.

    Vyvgart Hytrulo — Initial Therapy for CIDP

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has not failed a previous course of Vyvgart Hytrulo therapy.
    • Diagnosis of chronic inflammatory demyelinating polyneuropathy (CIDP), confirmed by progressive symptoms present for at least 2 months; symptomatic polyradiculoneuropathy indicated by progressive or relapsing motor or sensory impairment of more than one limb; and electrodiagnostic findings consistent with EFNS/PNS guidelines for definite CIDP.
    • At least one qualifying electrodiagnostic finding

      • Motor distal latency prolongation in 2 nerves.
      • Reduction of motor conduction velocity in 2 nerves.

    Vyvgart Hytrulo — Continuation Therapy for CIDP

    Covered when ALL of the following are met:

    ALL of the following

    • Patient has previously been treated with Vyvgart Hytrulo.
    • Documentation of positive clinical response to therapy as measured by an objective scale (e.g., Rankin, Modified Rankin, or Medical Research Council [MRC] scale).
    • Patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.
    • Vyvgart Hytrulo is dosed according to the FDA-labeled dosing for CIDP.
    • Prescribed by, or in consultation with, a neurologist.

    Generalized Myasthenia Gravis — Revised Antibody and Treatment-Failure Pathway

    The revised generalized myasthenia gravis pathway recognizes the following antibody-status categories and corresponding treatment-failure requirements:

    ALL of the following

    • Qualifying antibody status

      • Positive serologic test for anti-AChR antibodies.
      • Positive serologic test for anti-MuSK antibodies.
      • Positive serologic test for anti-LRP4 antibodies.
      • Negative serologic tests for anti-AChR, anti-MuSK, and anti-LRP4 antibodies (triple seronegative).
    • Corresponding treatment-failure pathway

    Imaavy, Rystiggo, Vyvgart, and Vyvgart Hytrulo must not be used in combination with one another or with other addressed FcRn blockers. These products must also not be used in combination with CD19-directed cytolytic antibodies, complement inhibitors, or immune globulin, as specified in the applicable product criteria.

    Vyvgart or Vyvgart Hytrulo must not be used in combination with a CD19-directed cytolytic antibody, complement inhibitor, another FcRn blocker, or immune globulin.

    U.S. Food and Drug Administration (FDA) approval alone is not a basis for coverage.

    Applicable Codes and Clinical Thresholds

    HCPCS CodesHCPCS
    J9256Injection, nipocalimab-aahu, 3 mg
    J9333Injection, rozanolixizumab-noli, 1 mg
    J9334Injection, efgartigimod alfa, 2 mg and hyaluronidase-qvfc
    Diagnosis CodesICD-10
    G70.0Chronic inflammatory demyelinating polyneuritis Myasthenia gravis
    G70.00Myasthenia gravis without (acute) exacerbation
    G70.01Myasthenia gravis with (acute) exacerbation
    Applicable CodesICD-10
    G70.0Myasthenia gravis without (acute) exacerbation
    MG-ADL baseline score
    Required baseline scoreMG-ADL total score of at least 5
    TimingMeasured at initiation of therapy
    Applies toInitial therapy for generalized myasthenia gravis
    MG-ADL continuation response
    Required responseAt least a 2-point improvement or maintenance from the pretreatment baseline
    MeasureReduction in the MG-ADL score

    Authorization and Documentation Requirements

    Prior Authorization

    12-Month Authorization Period

    Submit prior authorization for initial and continuation treatment. Initial authorization and each reauthorization are limited to no more than 12 months.

    • Imaavy, Rystiggo, Vyvgart, and Vyvgart Hytrulo require authorization.
    • Continuation authorization is also limited to 12 months.
    Billing Rule

    Benefit and Administration Channel

    These products are administered under the medical benefit when given by a healthcare professional. Self-administered subcutaneous Vyvgart Hytrulo is obtained under the pharmacy benefit unless the member-specific benefit plan provides otherwise.

    Policy Background

    FcRn blockers are used in this policy primarily for generalized myasthenia gravis (gMG), with Vyvgart Hytrulo also addressed for adult chronic inflammatory demyelinating polyneuropathy (CIDP). Coverage focuses on patients with clinically significant disease, documented functional impairment such as the MG-ADL requirements, and inadequate control or failure of specified prior treatment. For continuation, records must demonstrate measurable clinical benefit rather than escalation of baseline immunosuppressive therapy or additional rescue treatment.

    Clinical Definitions

    MGFA Clinical Classification
    Qualifying classesClass II, III, or IV
    ClassificationMyasthenia Gravis Foundation of America Clinical Classification
    TimingAt initiation of therapy
    MG-ADL initiation score
    ScaleMyasthenia Gravis Activities of Daily Living (MG-ADL)
    Initiation thresholdTotal score of at least 5
    UseAssesses eligibility for initial therapy

    Initial Therapy

    Imaavy Initial Therapy

    Imaavy initial therapy requires all of the following:

    Imaavy initial criteria

    • No previous Imaavy course has failed; the patient has gMG; anti-AChR or anti-MuSK serology is positive; MGFA class is II, III, or IV; and baseline MG-ADL is at least 5.
    • Treatment-failure pathway

      • ANY of the following

        • Failure of at least two immunosuppressive agents over at least 12 months.
        • Failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis, plasma exchange, and/or immune globulin over at least 12 months without symptom control.

    Continuation Therapy

    Imaavy Continuation

    Imaavy continuation requires all of the following:

    Continuation criteria

    • Prior Imaavy treatment; at least a 2-point MG-ADL improvement or maintenance from pretreatment baseline; reduced signs and symptoms of myasthenia gravis; and baseline immunosuppressive therapy maintained, reduced, or discontinued.
    • No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation.

    Rystiggo Continuation

    Rystiggo continuation requires all of the following:

    Continuation criteria

    • Prior Rystiggo treatment; at least a 2-point MG-ADL improvement or maintenance from pretreatment baseline; reduced signs and symptoms of myasthenia gravis; and baseline immunosuppressive therapy maintained, reduced, or discontinued.

    Required Prior Treatment

    StepCorticosteroid requirementImmune-globulin requirement
    1Trial and failure after at least 2 months, or contraindication or intoleranceTrial and failure after at least 3 months; or intolerance to all immune globulins with dose adjusted or escalated to the maximally allowable and/or tolerated dose

    Administration Setting

    Billing Rule

    Confirm the Vyvgart Hytrulo site of care

    This policy addresses products administered by a healthcare professional. Self-administered subcutaneous Vyvgart Hytrulo is generally obtained under the pharmacy benefit unless otherwise specified by the member-specific benefit plan; for UnitedHealthcare of California plans with a delegated provider group conducting prior authorization, it may be obtained under the medical benefit.

    Policy Summary
    PayerUnitedHealthcare
    PolicyFcRn Blockers
    Policy CodePolicy 2026D0111P
    Change TypeModified
    Effective DateOctober 1, 2026
    Next Review DateN/A
    Key ActionSubmit antibody-status and treatment-failure documentation supporting the applicable generalized myasthenia gravis criteria.
    SourceLink
    On This Page
    Coverage CriteriaApplicable Codes and Clinical ThresholdsAuthorization and Documentation RequirementsPolicy BackgroundClinical DefinitionsInitial TherapyContinuation TherapyRequired Prior TreatmentAdministration Setting
  1. Imaavy is dosed according to the FDA-labeled dosing for gMG.
  2. Prescribed by, or in consultation with, a neurologist.
  3. Reauthorization will be for no more than 12 months.
  4. MG-ADL total score ≥ 5 at initiation of therapy.
  5. ONE of the following treatment-failure pathways

    • If anti-AChR antibody positive

      • History of failure of at least two immunosuppressive agents over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.).
      • History of failure of at least one immunosuppressive therapy and required four or more courses of plasmapheresis/plasma exchanges and/or immune globulin over the course of at least 12 months without symptom control.
    • If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.).
  6. Patient is not receiving Rystiggo in combination with a CD19-directed cytolytic antibody [e.g., Uplizna (inebilizumab)], complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)], FcRn blocker [e.g., Imaavy (nipocalimab-aahu), Vyvgart (efgartigimod alfa-fcab), Vyvgart Hytrulo (efgartigimod alfa and hyaluronidase-qvfc)], or immune globulin (e.g., Hizentra, Privigen, Gammagard).
  7. Patient will be given Rystiggo no sooner than 63 days from the start of the previous treatment cycle.
  8. Rystiggo is dosed according to the FDA-labeled dosing for gMG.
  9. Prescribed by, or in consultation with, a neurologist.
  10. Initial authorization will be for no more than 12 months.
  11. Patient is not being given Rystiggo sooner than 63 days from the start of the previous treatment cycle.
  12. Rystiggo is dosed according to the FDA-labeled dosing for gMG.
  13. Prescribed by, or in consultation with, a neurologist.
  14. Reauthorization will be for no more than 12 months.
  15. Positive serologic test for anti-LRP4 antibodies.
  16. Negative serologic tests for anti-AChR, anti-MuSK, and anti-LRP4 antibodies (triple seronegative).
  17. MGFA Clinical Classification of class II, III, or IV at initiation of therapy.
  18. MG-ADL total score ≥ 5 at initiation of therapy.
  19. ONE of the following treatment-failure pathways

    • If anti-AChR positive, anti-LRP4 positive, or triple seronegative

      • History of failure of at least two immunosuppressive agents over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.).
      • History of failure of at least one immunosuppressive therapy and required four or more courses of plasmapheresis/plasma exchanges and/or immune globulin over the course of at least 12 months without symptom control.
    • If anti-MuSK antibody positive: history of failure of at least one immunosuppressive agent over the course of at least 12 months (e.g., azathioprine, corticosteroids, cyclosporine, methotrexate, mycophenolate, etc.).
  20. Patient is not receiving Vyvgart or Vyvgart Hytrulo in combination with a CD19-directed cytolytic antibody [e.g., Uplizna (inebilizumab)], complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)], FcRn blocker [e.g., Imaavy (nipocalimab-aahu), Rystiggo (rozanolixizumab-noli)], or immune globulin (e.g., Hizentra, Privigen, Gammagard).
  21. Vyvgart or Vyvgart Hytrulo is dosed according to the FDA-labeled dosing for gMG.
  22. Prescribed by, or in consultation with, a neurologist.
  23. Initial authorization will be for no more than 12 months.
  24. Patient is not receiving Vyvgart or Vyvgart Hytrulo in combination with a CD19-directed cytolytic antibody [e.g., Uplizna (inebilizumab)], complement inhibitor [e.g., eculizumab, Ultomiris (ravulizumab), Zilbrysq (zilucoplan)], FcRn blocker [e.g., Imaavy (nipocalimab-aahu), Rystiggo (rozanolixizumab-noli)], or immune globulin (e.g., Hizentra, Privigen, Gammagard).
  25. Vyvgart or Vyvgart Hytrulo is dosed according to the FDA-labeled dosing for gMG.
  26. Prescribed by, or in consultation with, a neurologist.
  27. Reauthorization will be for no more than 12 months.
  28. Vyvgart or Vyvgart Hytrulo is dosed according to FDA-labeled dosing for gMG.
  29. Prescribed by, or in consultation with, a neurologist.
  30. Reauthorization will be for no more than 12 months.
  31. Prolongation of F-wave latency in 2 nerves.
  32. Absence of F-waves in at least 1 nerve.
  33. Partial motor conduction block of at least 1 motor nerve.
  34. Abnormal temporal dispersion in at least 2 nerves.
  35. Distal CMAP duration increase in at least 1 nerve.
  36. Trial and failure, after a trial of at least 2 months, contraindication, or intolerance to corticosteroids.
  37. ONE of the following immune-globulin pathways

    • Trial and failure, after a trial of at least 3 months, to an immune globulin (intravenous or subcutaneous).
    • ALL of the following

      • Intolerance to all immune globulins (intravenous or subcutaneous).
      • Dose has been adjusted or escalated to the maximally allowable and/or tolerated dose.
    • Contraindication to all immune globulins (intravenous or subcutaneous).
  38. Patient is not receiving Vyvgart Hytrulo in combination with an immune globulin.
  39. Vyvgart Hytrulo is dosed according to the FDA-labeled dosing for CIDP.
  40. Prescribed by, or in consultation with, a neurologist.
  41. Initial authorization will be for no more than 12 months.
  42. Reauthorization will be for no more than 12 months.
    For anti-AChR-positive, anti-LRP4-positive, or triple-seronegative patients: history of failure of at least two immunosuppressive agents over at least 12 months, or failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchanges and/or immune globulin over at least 12 months without symptom control.
  43. For anti-MuSK-positive patients: history of failure of at least one immunosuppressive agent over at least 12 months.
  44. Continuation use
    Required for continuation or reauthorization
    Rystiggo treatment-cycle interval
    Minimum intervalNo sooner than 63 days
    Interval measured fromThe start of the previous treatment cycle
    ProductRystiggo
    Plasmapheresis, plasma exchange, and/or immune globulin history
    Required historyFour or more courses of plasmapheresis, plasma exchange, and/or immune globulin
    DurationOver at least 12 months
    Treatment outcomeWithout symptom control
    MG-ADL improvement
    Required improvementAt least a 2-point reduction in MG-ADL score
    Comparison pointPretreatment baseline
    UseDocuments clinical response during gMG continuation therapy
    Progressive CIDP symptoms
    Minimum durationProgressive CIDP symptoms present for at least 2 months
    Associated conditionChronic inflammatory demyelinating polyneuropathy
    Therapy contextInitial Vyvgart Hytrulo therapy for CIDP
    Corticosteroid trial
    Required trialTrial and failure of corticosteroids after at least 2 months
    Alternative pathwaysA contraindication or intolerance to corticosteroids may satisfy the requirement
    IndicationCIDP initial therapy
    Immune-globulin trial
    Required trialTrial and failure of an immune globulin after at least 3 months
    Alternative pathwaysIntolerance to all immune globulins with maximal allowable or tolerated dose adjustment, or contraindication to all immune globulins
    IndicationCIDP initial therapy
    • Exception: for UnitedHealthcare of California plans with a delegated provider group conducting the prior authorization review, self-administered Vyvgart Hytrulo may be obtained under the medical benefit.
    Prior Authorization

    Vyvgart Prescriber and Duration Requirements

    For Vyvgart or Vyvgart Hytrulo, document FDA-labeled dosing and prescribing by, or consultation with, a neurologist. For gMG, initial and reauthorization periods may not exceed 12 months; for CIDP, the same requirements apply to Vyvgart Hytrulo.

    • Vyvgart and Vyvgart Hytrulo are administered IV or SC as applicable to the product.
    • Vyvgart Hytrulo must be dosed according to FDA-labeled CIDP dosing for CIDP treatment.
    Prior Authorization

    Revised gMG Prior Authorization Criteria

    The revised gMG criteria require documentation of the applicable antibody status and treatment-failure pathway. For Vyvgart products, qualifying serology includes anti-AChR, anti-MuSK, anti-LRP4, or triple-seronegative results; the required prior-treatment pathway depends on antibody status.

    • For anti-AChR, anti-LRP4, or triple-seronegative patients: failure of at least two immunosuppressive agents for at least 12 months, or failure of at least one immunosuppressive therapy plus four or more courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.
    • For anti-MuSK-positive patients: failure of at least one immunosuppressive agent over at least 12 months.
    Step Therapy

    Required CIDP Prior Treatment

    Before requesting Vyvgart Hytrulo for CIDP, document the required corticosteroid and immune-globulin treatment history, including trial duration and any failure, contraindication, or intolerance.

    • Corticosteroids: trial and failure after at least 2 months, or contraindication or intolerance.
    • Immune globulin: trial and failure after at least 3 months; alternatively, intolerance to all immune globulins with maximally allowable or tolerated dose adjustment/escalation, or contraindication to all immune globulins.
    Documentation Required

    Initial Clinical Documentation

    For initial therapy, submit chart notes, laboratory and serologic results, and treatment records confirming the diagnosis, disease severity, MG-ADL threshold, applicable antibody status, and required prior-treatment history.

    • Confirm gMG diagnosis and MGFA Clinical Classification II, III, or IV at initiation.
    • Document MG-ADL total score of at least 5 at initiation.
    • Provide positive anti-AChR or anti-MuSK serology for Imaavy and Rystiggo; for Vyvgart products, provide positive anti-AChR, anti-MuSK, or anti-LRP4 serology, or negative results for all three antibodies.
    • Document that the patient has not failed a previous course of the requested product.
    Documentation Required

    Continuation Documentation

    Continuation requests must include records showing prior treatment with the requested product and clinically meaningful benefit, including MG-ADL improvement or maintenance and reduced gMG signs and symptoms.

    • Document at least a 2-point reduction in MG-ADL score from pretreatment baseline.
    • Document maintenance, reduction, or discontinuation of baseline immunosuppressive therapy when applicable.
    • For Vyvgart products, identify whether the prior product was Vyvgart, Vyvgart Hytrulo, or both.
    Documentation Required

    Prior-Treatment Failure Documentation

    Provide treatment records establishing the required immunosuppressive-agent failures and, where applicable, rescue-treatment history before initial gMG authorization.

    • For anti-AChR-positive, anti-LRP4-positive, or triple-seronegative gMG: document failure of at least two immunosuppressive agents over at least 12 months, or failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis/plasma exchange and/or immune globulin over at least 12 months without symptom control.
    • For anti-MuSK-positive gMG: document failure of at least one immunosuppressive agent over at least 12 months.
    • Include agent names, treatment dates and duration, response or failure, and rescue-treatment dates when used.
    Documentation Required

    gMG Continuation Records

    For gMG continuation, the medical record must support the required MG-ADL response and ongoing clinical benefit from therapy.

    • Show at least a 2-point MG-ADL reduction from pretreatment baseline, with improvement or maintenance documented over time.
    • Document reduced signs and symptoms of myasthenia gravis.
    • Record any escalation or addition of immunosuppressive or rescue therapy, which may indicate treatment failure.
    Documentation Required

    CIDP Diagnostic and Treatment History

    For CIDP requests, document the symptom course, objective electrodiagnostic findings, and required corticosteroid and immune-globulin treatment history.

    • Progressive symptoms must be present for at least 2 months, with progressive or relapsing motor or sensory impairment in more than one limb.
    • Provide electrodiagnostic findings consistent with EFNS/PNS guidelines for definite CIDP, including at least one qualifying abnormality such as abnormalities in motor distal latency, motor conduction velocity, F-wave latency or presence, conduction block, temporal dispersion, or distal CMAP duration.
    • Document corticosteroid and immune-globulin trial, failure, contraindication, or intolerance as applicable.
    Documentation Required

    CIDP Response Documentation

    Continuation of Vyvgart Hytrulo for CIDP requires objective evidence of positive clinical response and ongoing compliance with product and combination-therapy requirements.

    • Use an objective clinical-response scale, such as Rankin, Modified Rankin, or Medical Research Council (MRC) scale.
    • Document that Vyvgart Hytrulo is not being used with an immune globulin.
    • Confirm FDA-labeled dosing and neurologist prescribing or consultation.
    Documentation Required

    gMG Diagnostic and Treatment-Failure Documentation

    For revised gMG criteria, submit antibody testing and the treatment history applicable to the result. The revised policy recognizes anti-AChR, anti-MuSK, anti-LRP4, and triple-seronegative status for Vyvgart products.

    • Document positive anti-AChR, anti-MuSK, or anti-LRP4 serology, or negative anti-AChR, anti-MuSK, and anti-LRP4 serology.
    • Match treatment-failure documentation to antibody status: two failed immunosuppressive agents or the qualifying rescue-treatment pathway for anti-AChR, anti-LRP4, or triple-seronegative patients; one failed immunosuppressive agent for anti-MuSK-positive patients.
    Denial Risk

    Imaavy Initial Authorization Denial Risks

    Imaavy may be denied when initial gMG, antibody, severity, MG-ADL, or prior-treatment requirements are not documented.

    • No confirmed gMG diagnosis, qualifying anti-AChR or anti-MuSK serology, MGFA class II-IV status, or MG-ADL score of at least 5.
    • Required immunosuppressive-agent or rescue-treatment failure is absent or insufficient.
    • A previous Imaavy course was failed, or the submission does not establish that a previous course was not failed.
    Denial Risk

    Rystiggo Initial Authorization Denial Risks

    Rystiggo may be denied when the required antibody, disease-severity, MG-ADL, or prior-treatment criteria are unmet or unsupported.

    • No confirmed gMG diagnosis, qualifying anti-AChR or anti-MuSK serology, MGFA class II-IV status, or MG-ADL score of at least 5.
    • Required immunosuppressive-agent or rescue-treatment failure is absent or insufficient.
    • A previous Rystiggo course was failed, or treatment is requested less than 63 days from the start of the prior treatment cycle.
    Denial Risk

    Vyvgart Initial Authorization Denial Risks

    Vyvgart or Vyvgart Hytrulo may be denied when gMG, revised antibody-status, severity, or treatment-failure requirements are not established.

    • No confirmed gMG diagnosis, qualifying antibody result or triple-seronegative result, MGFA class II-IV status, or MG-ADL score of at least 5.
    • Required antibody-specific immunosuppressive-agent or rescue-treatment failure is absent or insufficient.
    • A previous course of Vyvgart or Vyvgart Hytrulo was failed.
    Denial Risk

    Continuation Treatment Failure

    Continuation authorization may be denied when the required clinical response is absent, dosing or prescriber requirements are not met, or treatment-failure indicators are present.

    • No documented at least 2-point MG-ADL improvement or maintenance, or no reduction in gMG signs and symptoms.
    • Dosing is not FDA-labeled, the neurologist requirement is unmet, or the authorization period exceeds 12 months.
    • Add-on or escalated baseline immunosuppressive therapy or additional rescue therapy for gMG or exacerbation while on treatment is considered treatment failure.
    • For Rystiggo, administration sooner than 63 days from the prior cycle may result in denial.
    Denial Risk

    Prohibited Combination Therapy

    Do not request these FcRn blockers in prohibited combination regimens. Combination use may result in denial for both initial and continuation authorization.

    • Do not combine with a CD19-directed cytolytic antibody, such as Uplizna.
    • Do not combine with a complement inhibitor, another FcRn blocker, or immune globulin for gMG.
    • Do not combine Vyvgart Hytrulo for CIDP with an immune globulin.
    Denial Risk

    gMG Treatment Failure

    For gMG continuation, escalation or addition of baseline immunosuppressive therapy, or additional rescue therapy to treat myasthenia gravis or symptom exacerbation while on treatment, is considered treatment failure.

    • Document maintenance, reduction, or discontinuation of baseline immunosuppressive therapy when applicable.
    • Explain any new immunosuppressive or rescue treatment and its relationship to disease control.
    Denial Risk

    Insufficient CIDP Qualification

    Vyvgart Hytrulo for CIDP may be denied when the diagnosis, electrodiagnostic testing, or required corticosteroid and immune-globulin treatment history is insufficient.

    • Symptoms must be progressive for at least 2 months and involve progressive or relapsing motor or sensory impairment of more than one limb.
    • Electrodiagnostic findings must include at least one qualifying abnormality consistent with EFNS/PNS definite CIDP criteria.
    • Required corticosteroid and immune-globulin trials, failures, contraindications, or intolerances must be documented.
    Denial Risk

    Failure to Meet Revised gMG Criteria

    Initial gMG authorization may be denied when the revised antibody-status or antibody-specific treatment-failure criteria are not met.

    • For Vyvgart products, qualifying status is anti-AChR-positive, anti-MuSK-positive, anti-LRP4-positive, or triple-seronegative.
    • For anti-AChR, anti-LRP4, or triple-seronegative patients, document the required two-agent failure or qualifying rescue-treatment history.
    • For anti-MuSK-positive patients, document failure of at least one immunosuppressive agent over at least 12 months.
    Triple seronegative
    Anti-AChR testNegative
    Anti-MuSK testNegative
    Anti-LRP4 testNegative
    MG-ADL
    Scale structureEight-item scale assessing the effect of generalized myasthenia gravis on daily functions
    Score range0 to 24
    Score interpretationHigher scores indicate greater impairment
    QMG
    Scale structure13-item categorical scale assessing muscle weakness
    Score range0 to 39
    Score interpretationHigher scores indicate more severe impairment
    CIDP
    DiseaseChronic inflammatory demyelinating polyneuropathy
    CourseProgressive or relapsing symptomatic polyradiculoneuropathy
    Impairment and confirmationMotor or sensory impairment of more than one limb with qualifying electrodiagnostic findings consistent with EFNS/PNS criteria
    Typical CIDP
    PatternProgressive or relapsing, symmetric, proximal and distal weakness of the upper and lower limbs
    Sensory involvementSensory involvement of at least two limbs
    Additional featuresDeveloping over at least 8 weeks, with absent or reduced tendon reflexes in all limbs
    CIDP variants
    Distal and multifocal formsDistal, multifocal, and focal CIDP
    Motor and sensory formsMotor and sensory CIDP
    Relationship to typical CIDPVariants otherwise follow the typical CIDP pattern; tendon reflexes may remain normal in unaffected limbs
    For anti-MuSK-positive disease, failure of at least one immunosuppressive agent over at least 12 months.
  45. No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation.
  46. Rystiggo Initial Therapy

    Rystiggo initial therapy requires all of the following:

    Rystiggo initial criteria

    • No previous Rystiggo course has failed; the patient has gMG; anti-AChR or anti-MuSK serology is positive; MGFA class is II, III, or IV; and baseline MG-ADL is at least 5.
    • Treatment-failure pathway

      • ANY of the following

        • Failure of at least two immunosuppressive agents over at least 12 months.
        • Failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis, plasma exchange, and/or immune globulin over at least 12 months without symptom control.
      • For anti-MuSK-positive disease, failure of at least one immunosuppressive agent over at least 12 months.
    • No prohibited combination therapy; treatment is given no sooner than 63 days from the start of the previous cycle; FDA-labeled gMG dosing; neurologist prescribing or consultation.

    Vyvgart/Vyvgart Hytrulo Initial Therapy

    Vyvgart or Vyvgart Hytrulo initial therapy requires all of the following:

    Initial gMG criteria

    • No previous Vyvgart or Vyvgart Hytrulo course has failed; the patient has gMG; antibody status is anti-AChR-positive, anti-MuSK-positive, anti-LRP4-positive, or triple seronegative; MGFA class is II, III, or IV; and baseline MG-ADL is at least 5.
    • Treatment-failure pathway

      • ANY of the following

        • For anti-AChR-positive, anti-LRP4-positive, or triple-seronegative disease, failure of at least two immunosuppressive agents over at least 12 months.
        • For anti-AChR-positive, anti-LRP4-positive, or triple-seronegative disease, failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis, plasma exchange, and/or immune globulin over at least 12 months without symptom control.
      • For anti-MuSK-positive disease, failure of at least one immunosuppressive agent over at least 12 months.
    • No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation.

    CIDP Initial Therapy

    Vyvgart Hytrulo initial CIDP therapy requires all diagnostic, prior-treatment, dosing, combination, authorization, and prescriber criteria:

    CIDP initial criteria

    • No previous Vyvgart Hytrulo course has failed.
    • CIDP is confirmed by progressive symptoms for at least 2 months, symptomatic motor or sensory polyradiculoneuropathy affecting more than one limb, and qualifying electrodiagnostic findings.
    • Corticosteroid requirement

      • Corticosteroid trial and failure after at least 2 months.
      • Contraindication or intolerance to corticosteroids.
    • Immune-globulin requirement

      • Immune-globulin trial and failure after at least 3 months.
      • Intolerance to all immune globulins despite adjustment or escalation to the maximally allowable and/or tolerated dose.
      • Contraindication to all immune globulins.
    • Vyvgart Hytrulo is not administered with immune globulin, is dosed according to FDA-labeled CIDP dosing, and is prescribed by, or in consultation with, a neurologist.

    Initial gMG Therapy

    For initial gMG therapy, apply both the applicable serologic eligibility and treatment-failure pathway:

    Initial gMG decision logic

    • Serologic eligibility

      • Positive anti-AChR antibody.
      • Positive anti-MuSK antibody.
      • Positive anti-LRP4 antibody.
      • Negative anti-AChR, anti-MuSK, and anti-LRP4 antibodies (triple seronegative).
    • Treatment history for anti-AChR-positive, anti-LRP4-positive, or triple-seronegative patients

      • Failure of at least two immunosuppressive agents over at least 12 months.
      • Failure of at least one immunosuppressive therapy plus at least four courses of plasmapheresis, plasma exchange, and/or immune globulin over at least 12 months without symptom control.
    • Treatment history for anti-MuSK-positive patients: Failure of at least one immunosuppressive agent over at least 12 months.
  47. No prohibited combination therapy; treatment is given no sooner than 63 days from the start of the prior cycle; FDA-labeled gMG dosing; neurologist prescribing or consultation.
  48. Vyvgart/Vyvgart Hytrulo Continuation

    Vyvgart or Vyvgart Hytrulo continuation requires all of the following:

    Continuation criteria

    • Prior Vyvgart or Vyvgart Hytrulo treatment; at least a 2-point MG-ADL improvement or maintenance from pretreatment baseline; reduced signs and symptoms of myasthenia gravis; and baseline immunosuppressive therapy maintained, reduced, or discontinued.
    • No prohibited combination therapy; FDA-labeled gMG dosing; neurologist prescribing or consultation.

    Continuation Therapy

    Continuation therapy requires all applicable prior-treatment, clinical-response, dosing, neurologist, and compliance requirements:

    Continuation requirements

    • Indication-specific prior treatment and response

      • gMG

        • The patient has previously received Vyvgart or Vyvgart Hytrulo; MG-ADL has improved by at least 2 points from pretreatment baseline; signs and symptoms have been reduced; and baseline immunosuppressive therapy has been maintained, reduced, or discontinued.
      • CIDP

        • The patient has previously received Vyvgart Hytrulo and has a positive clinical response documented using an objective scale such as Rankin, Modified Rankin, or MRC.
    • Applicable combination-therapy restrictions are met: gMG treatment is not combined with a CD19-directed cytolytic antibody, complement inhibitor, another FcRn blocker, or immune globulin; CIDP treatment is not combined with immune globulin.
    • Dosing follows FDA-labeled dosing for the applicable indication, and treatment is prescribed by, or in consultation with, a neurologist.